Corporate Watchdog to Fine Pharmaceutical Companies for Unfair Practices (South Korea)
This article was originally published in PharmAsia News
South Korea's Fair Trade Commission (FTC) has announced it will be taking action against 10 pharmaceutical companies for allegedly offering financial incentives to hospitals and doctors to give priority to their products. Alleged incentives included cash, rebates, dinners, and covering travel expenses. Several companies are also accused of setting wholesaler prices to keep drug costs up. The FTC has not released the exact amount of the financial penalties it will seek. Insiders speculate the fines for some companies may go as high as $108 million. These accusations are the result of a year-long investigation by the FTC into the trading practices of 11 local companies, six foreign entities, and six wholesalers. (Click here for more
You may also be interested in...
South Korean Fair Trade Commission Investigates Drug Makers For Offering Unethical Financial Incentives To Hospitals
SEOUL - South Korea's Fair Trade Commission is in the final stages of investigations into seven pharmaceutical companies including five foreign pharma companies in a series of complaints from civic groups that drug makers were offering financial incentives to hospitals and doctors to give priority to their products
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.